| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
* From the Department of Anesthesia and Intensive Care, Department of Hematology,
Haemostasis Unit, Department of Cardiovascular Surgery and
Department of Cardiology,
CHU Nancy-Brabois, Vandoeuvre-les-Nancy, France.
Address correspondence to: Dan Longrois MD PhD, Department of Anesthesia and Intensive Care, CHU Nancy- Brabois, 4, rue du Morvan 54500 Vandoeuvre les Nancy, France. Phone: 33-3-83-15-41-66; Fax: 33-3-83-15-36-88; E-mail: d.longrois{at}chu-nancy.fr
Purpose: To report the case of a patient with HIT that received a prolonged infusion of r-hirudin (lepirudin; Refludan®; Hoechst, France) before, during and after cardiopulmonary bypass (CPB) for aortic surgery. Although administration of r-hirudin for CPB anticoagulation has previously been reported, many questions persist concerning the best therapeutic regimen for CPB anticoagulation as well as the time of onset and the doses for postoperative anticoagulation.
Clinical Features: A 65-yr-old man was admitted for surgery of aortic stenosis after an episode of acute pulmonary edema complicated by deep venous thrombosis in the context of documented HIT. The patient received r-hirudin for 13 dy before surgery at doses (0.4 mg•kg–1 bolus followed by 0.15 mg•kg–1•hr–1 continuous infusion) that maintained activated partial thromboplastin time (aPTT) ratios between 2 and 2.5. Anticoagulation for CPB was performed with r-hirudin given as 0.1 mg•kg–1 iv bolus and 0.2 mg•kg–1 in the CPB priming volume. Anticoagulation during CPB was monitored with the whole blood activated coagulation time and ecarin clotting time (ECT) performed in the operating room with values corresponding to r-hirudin concentrations > 5 µg•ml–1 during CPB. Anticoagulation during CPB was uneventful. Two bleeding episodes, related to the r-hirudin regimen and necessitating allogeneic blood transfusion, occurred after surgery.
Conclusion: This case report confirms previous experience of the use of r-hirudin for anticoagulation during CPB and provides additional information in the context of prolonged r-hirudin infusion before and after CPB.
This article has been cited by other articles:
 |
|
 |
|
  E. de Maistre, Y. Gruel, and D. Lasne Diagnosis and management of heparin-induced thrombocytopenia: [Le diagnostic et le traitement de la thrombopenie induite par l'heparine]. Can J Anesth, June 1, 2006; 53(6_suppl): S123 - S134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Stratmann, A. M. deSilva, E. E. Tseng, J. Hambleton, M. Balea, A. J. Romo, M. J. Mann, N. L. Achorn, W. F. Moskalik, and C. W. Hoopes Reversal of Direct Thrombin Inhibition After Cardiopulmonary Bypass in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., June 1, 2004; 98(6): 1635 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Alving How I treat heparin-induced thrombocytopenia and thrombosis Blood, January 1, 2003; 101(1): 31 - 37. [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. R. Walker and D. Royston Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies Br. J. Anaesth., June 1, 2002; 88(6): 848 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Despotis, C. W. Hogue, R. Saleem, M. Bigham, N. Skubas, I. Apostolidou, A. Qayum, and J. H. Joist The Relationship Between Hirudin and Activated Clotting Time: Implications for Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiac Surgery Anesth. Analg., July 1, 2001; 93(1): 28 - 32. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
